Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TERNS PHARMACEUTICALS, INC.

(TERN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

06/13/2021 | 05:00pm EDT

FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with NASH. Webcast and conference call details are as follows:

Webcast link: https://edge.media-server.com/mmc/p/2gsxxmta

Live Conference Call
Domestic Callers (U.S./Canada toll-free): (833) 665-0612
International Callers: (929) 517-0403
Conference ID: 7587739

Following the live audio webcast, a replay will be available on the investors page of the Terns Pharmaceuticals website at http://ir.ternspharma.com for 30 days.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit www.ternspharma.com.

Contacts for Terns:

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com


Primary Logo


© GlobeNewswire 2021
All news about TERNS PHARMACEUTICALS, INC.
06/24TERNS PHARMACEUTICALS : Starts Patient Dosing in Phase 1b Trial of Liver Disease..
MT
06/24Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinic..
GL
06/24Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinic..
CI
06/21TERNS PHARMACEUTICALS, INC.(NASDAQGS : TERN) added to S&P Global BMI Index
CI
06/14TERNS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
06/14TERNS PHARMACEUTICALS : Reports Positive Top-line Results from Phase 2a LIFT Stu..
PU
06/14TERNS PHARMACEUTICALS : Reports Positive Results in Study of Drug Candidate for ..
MT
06/14Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agoni..
GL
06/14Terns Pharmaceuticals, Inc. Reports Positive Top-Line Results from Phase 2a L..
CI
06/13Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results fro..
GL
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,8 M - -
Net cash 2021 102 M - -
P/E ratio 2021 -2,12x
Yield 2021 -
Capitalization 188 M 188 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 98,9%
Chart TERNS PHARMACEUTICALS, INC.
Duration : Period :
Terns Pharmaceuticals, Inc. Technical Analysis Chart | TERN | US8808811074 | MarketScreener
Technical analysis trends TERNS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,50 $
Average target price 30,50 $
Spread / Average Target 307%
EPS Revisions
Managers and Directors
Senthil Sundaram Chief Executive Officer & Director
Erin Quirk President & Chief Medical Officer
Mark J. Vignola Chief Financial Officer & Treasurer
David A. Fellows Chairman
Weidong Zhong Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TERNS PHARMACEUTICALS, INC.0.00%188
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837